+
+

Celularity’s mission is to harness the power
of the living cell to augment biology,
immunity and longevity.

meet celularity

Celularity is a biotechnology company that productizes allogeneic cells and tissues derived from the postpartum placenta. These materials have the ability to augment our immunity and longevity by amplifying the body’s ability to fight disease, heal, and regenerate itself.

why the placenta?

Celularity is the only company to use an allogenic placental platform. Because stem cells derived from the placenta are intrinsically safe, they can be taken from any placenta and injected into any human without the risk of rejection. These cells are also incredibly abundant, making treatments more affordable and immediate.

130M

BIRTHS PER YEAR
GLOBALLY

<.01%

OF PLACENTAS
ARE UTILIZED

1

PLACENTA

=

100K+

MEDICAL TREATMENTS

big vision

AUGMENTED IMMUNITY

Celularity, through its strategic partner Sorrento Therapeutics, has acquired a powerful toolset to engineer cells for broad immunotherapeutic applications.

These include proprietary antibody and Chimeric Antigen Receptor (CAR) constructs that will allow Celularity to offer the world’s first immunotherapeutic suite of products against novel targets for cancer and immune disease. In addition, Celularity discovered a Natural Killer cell from the placenta and is actively developing therapeutic uses.

Celularity is developing the world’s first allogeneic off-the-shelf CAR-T cell receptor and CAR-NK products against a number of validated targets for immuno-oncology.

AUGMENTED LONGEVITY

Studies have shown as we age the population of stem cells resident in our organs and tissues declines exponentially, diminishing our body’s ability to heal and repair itself. Moreover, during our lifetime, our stem cells are damaged by environmental exposures rendering them less effective and adaptable.

By replenishing our reservoir of stem cells –– nature’s repair kit –– on an ongoing basis, we can augment our longevity.

Celularity seeks to make 100 years old the new 60, and to provide people with maximal aesthetics, mobility, and cognition as they age. We believe the 20 years of science, research, and intellectual property Celularity is built on is the cornerstone for the coming longevity revolution.

our pipeline

Celularity’s placental technology platform uses stem cells derived from the placenta to create therapeutic options for complex medical conditions ranging from cancer to Crohn’s disease. Celularity is the leader in cellular medicine with the deepest and broadest intellectual property portfolio of more than 800 issued patents.



our science

Read the latest publications relating to Celularity’s science.

our legacy

our founder

BOB HARIRI, MD, PhD

FOUNDER, CHAIRMAN & CEO

Dr. Robert (Bob) Hariri is the Founder, Chairman and CEO of Celularity.

He has worked for the past 20 years to transform the field of biomedicine where his discoveries and contributions to the study of stem cells and tissue engineering have sparked the development of nearly all existing stem cell therapies. In addition to Celularity, he is the Founder, and former Chairman and CEO of Celgene Cellular Therapeutics, a division of Celgene Corporation. He is also the Co-Founder and Vice Chairman of Human Longevity Inc.

LEADERSHIP TEAM

jay-kaminski

JAY KAMINSKI

CHIEF OPERATING OFFICER

Celgene

john-haines

JOHN R. HAINES

EVP, CHIEF ADMINISTRATIVE OFFICER

LifebankUSA, Anthrogenesis

xiaokui-zhang

XIAOKUI ZHANG, PHD

EVP, CHIEF SCIENTIFIC OFFICER

Celgene, Rockefeller University

jodi-gurney

JODI GURNEY

EVP, CHIEF INNOVATION OFFICER

CCT, Celgene

timothy-smith

TIMOTHY L. SMITH, JD PHD

EVP, GENERAL COUNSEL

Human Longevity, Novartis

curt-quigley

CURT QUIGLEY

SVP, CHIEF COMMERCIAL OFFICER

Celgene, Pfizer, Pharmacia

carlos-remirez

CARLOS RAMIREZ

SVP, INVESTOR & PUBLIC RELATIONS

JP Morgan, American Express

bill-waller

BILL WALLER

SVP, FINANCE & CONTROLLER

Celgene, Hearst

beth-steinbrenner

BETH STEINBRENNER

SVP, HUMAN RESOURCES

Celgene, Nabisco, Kraft Foods

BOARD OF DIRECTORS

peter-diamandis

PETER DIAMANDIS, MD

CO-FOUNDER & VICE CHAIRMAN

Dr. Peter Diamandis is the Founder & Executive Chairman of the XPRIZE and Executive Founder of Singularity University. He has Co-Founded 20 companies including Human Longevity Inc. Diamandis is the NY Times Bestselling author of Abundance & BOLD. He earned degrees in Molecular Genetics and Aerospace Engineering at MIT, and an M.D. from Harvard Medical School. Fortune Magazine recently named Diamandis as on of the World’s 50 Greatest Leaders.

john-sculley

JOHN SCULLEY

VICE CHAIRMAN

John Sculley is an American businessman and formerly Chief Executive Officer of Apple Inc and President of Pepsi-Cola. The companies John has advised cover many industries: health-tech (RxAdvance, Rally Health, MDLIVE, FLEXPharma, SleepMed); fin-tech (Lantern Credit); mobile-tech (MetroPCS); and marketing-tech (Zeta Interactive). Sculley received a bachelor’s degree in Architectural Design from Brown University and an MBA from the Wharton School of the University of Pennsylvania.

bill-maris

BILL MARIS

BOARD MEMBER

Founder, Section 32

andrew-c-von-eschenbach

ANDREW C. VON ESCHENBACH, MD

BOARD MEMBER

Former Commissioner, United States FDA

henri-ji

HENRI JI, PhD

BOARD MEMBER

Co-Founder & CEO, Sorrento Therapeutics

jaisim-shah

JAISIM SHAH

BOARD MEMBER

Chief Executive Officer, Senmur Pharmaceuticals

andrew-pecora

ANDREW PECORA, MD, FACP, CPE

BOARD MEMBER

Chief Innovation Officer, John Thereur Cancer Center

david-deming

DAVID DEMING

BOARD MEMBER

Former Head, JPM Healthcare Investment Banking Group

STRATEGIC PARTNERS